Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Andrew Lassman MD
To determine the therapeutic efficacy of dasatinib in all patients (i.e., stages 1B and 2 combined) with recurrent/progressive GBM as measured by 6-month progression-free survival.
Data for this trial is being collected via the NRG/RTOG Data Center.
Patients with GBM who have progressive/recurrent disease despite treatment with radiotherapy and temozolomide. Patients accrued to stage 1 (closed to accrual) or stage 1B (opened to accrual May 5, 2009) require overexpression/activity in at least two of the following SRC, KIT, PDGFR, and EPHA2. Patients accrued to stage 2 (cohort closed; not currently applicable) do not require overexpression/activity.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.